Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price

Executive Summary

Amgen and Novartis won the first US FDA approval for a CGRP inhibitor in the prevention of migraine headaches. The companies aim to quickly capture a big share of what they estimate to be an 8m-patient market in the US with a $6,900 per year price tag.

Advertisement

Related Content

No More Deal? Novartis, Amgen Trade Lawsuits Over Aimovig Agreements
Can Lilly’s Cluster Headache Data Differentiate Its CGRP Inhibitor?
Teva Pushes CGRP Timeline Back To End Of 2018
Allergan's Ubrogepant Succeeds In Second Acute Migraine Phase III Study
New Migraine Drugs May Not Be Cost Effective In Patients With Other Options, ICER Suggests
Erenumab Moves Ahead In Treatment-Refractory Migraine in Novartis/Amgen LIBERTY Study
Outcomes Claim May Help Amgen Make Case For PCSK9 Inhibitor Repatha
Novartis Floats 'Bold' Value-Based Reimbursement Idea In Migraine
Amgen Plans 2017 Filings After Second Phase III CGRP Inhibitor Success
Repatha OK'd; Payers Eye PCSK9 Rebate/Discount War

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123110

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel